Samsca(tolvaptan)
Jinarc, Jynarque, Samsca, Tolvaptan (tolvaptan) is a small molecule pharmaceutical. Tolvaptan was first approved as Tolvaptan accord on . It is used to treat hyponatremia in the USA. It has been approved in Europe to treat autosomal dominant polycystic kidney and inappropriate adh syndrome. The pharmaceutical is active against vasopressin V2 receptor. In addition, it is known to target vasopressin V1a receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Jynarque, Samsca, Tolvaptan (discontinued: Samsca)
Drug Products
FDA
EMA
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| hyponatremia | — | D007010 | E87.1 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TOLVAPTAN, JYNARQUE, OTSUKA | |||
| 2025-04-23 | ODE-178 | ||
HCPCS
No data
Clinical
Clinical Trials
117 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | — | 4 | 7 | 4 | 3 | 18 |
| Hyponatremia | D007010 | — | E87.1 | — | 1 | 10 | 1 | 3 | 15 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | 1 | 4 | 1 | — | 6 |
| Diabetes insipidus | D003919 | — | E23.2 | 1 | 1 | 2 | 2 | 1 | 6 |
| Healthy volunteers/patients | — | — | — | 2 | 1 | — | 1 | — | 4 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | 1 | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 1 | — | 1 |
| Ascites | D001201 | — | R18 | — | — | — | 1 | — | 1 |
| Neoplasms | D009369 | — | C80 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycystic kidney diseases | D007690 | — | Q61.3 | — | 5 | 9 | — | 2 | 16 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 5 | 9 | — | 1 | 15 |
| Autosomal dominant polycystic kidney | D016891 | EFO_1001496 | Q61.2 | — | 5 | 7 | — | 2 | 14 |
| Arthrogryposis | D001176 | EFO_0003857 | Q74.3 | — | 4 | 7 | — | — | 11 |
| Inappropriate adh syndrome | D007177 | EFO_1000982 | E22.2 | 1 | 1 | 4 | — | 2 | 7 |
| Fibrosis | D005355 | — | — | — | 1 | 4 | — | — | 5 |
| Edema | D004487 | — | R60.9 | — | 2 | 3 | — | — | 5 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 3 | 1 | — | — | 4 |
| Cardiac edema | D004489 | EFO_1001771 | — | — | — | 3 | — | — | 3 |
| Autosomal recessive polycystic kidney | D017044 | — | Q61.1 | — | — | 2 | — | — | 2 |
Show 6 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Renal insufficiency | D051437 | — | N19 | — | 3 | — | — | 1 | 4 |
| Chronic kidney failure | D007676 | EFO_0003884 | N18.6 | — | 3 | — | — | — | 3 |
| Hypovolemia | D020896 | — | E86 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Urolithiasis | D052878 | — | N20-N23 | — | — | — | — | 1 | 1 |
| Urinary calculi | D014545 | — | N20.9 | — | — | — | — | 1 | 1 |
| Cystinuria | D003555 | — | E72.01 | — | — | — | — | 1 | 1 |
| Brain injuries | D001930 | — | S06.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tolvaptan |
| INN | tolvaptan |
| Description | Tolvaptan is a benzazepine derivative incorporating a benzenedicarboxamide function whch is a selective vasopressin V2 receptor antagonist used to treat euvolemic and hypervolemic hyponatremia. It is also used in the treatment of rapidly progressing autosomal dominant polycystic kidney disease to slow the rate of cyst development and renal insufficiency. Tolvaptan is a racemate consisting of a 1:1 mixture of 5R and 5S stereomers. It has a role as a vasopressin receptor antagonist and an aquaretic. It is a benzazepine and a benzenedicarboxamide. |
| Classification | Small molecule |
| Drug class | aptamers, classical and mirror; vasopressin receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(O)c3cc(Cl)ccc32)c(C)c1 |
Identifiers
| PDB | — |
| CAS-ID | 150683-30-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL344159 |
| ChEBI ID | 32246 |
| PubChem CID | 216237 |
| DrugBank | DB06212 |
| UNII ID | 21G72T1950 (ChemIDplus, GSRS) |
Target
Agency Approved
Alternate
AVPR1A
AVPR1A
Organism
Homo sapiens
Gene name
AVPR1A
Gene synonyms
AVPR1
NCBI Gene ID
Protein name
vasopressin V1a receptor
Protein synonyms
Antidiuretic hormone receptor 1a, AVPR V1a, SCCL vasopressin subtype 1a receptor, V1-vascular vasopressin receptor AVPR1A, V1a vasopressin receptor, Vascular/hepatic-type arginine vasopressin receptor
Uniprot ID
Mouse ortholog
Avpr1a (54140)
vasopressin V1a receptor (Q9QYH2)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,929 documents
View more details
Safety
Black-box Warning
Black-box warning for: Jynarque, Samsca, Tolvaptan
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,532 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use